Benzylthiouracil
 | |
| Systematic (IUPAC) name | |
|---|---|
|
1-(1-cyclohexa-2,4-dienylmethyl)-7-thia- 3,5-diazabicyclo[4.1.0]hepta-3,5-dien-2-one | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Oral | |
| Pharmacokinetic data | |
| Excretion | Renal |
| Identifiers | |
6336-50-1  | |
| H03BA03 | |
| PubChem | CID 685814 |
| ChemSpider |
597542 |
| UNII |
PZ35LUM333 |
| ChEMBL | CHEMBL1491306 |
| Chemical data | |
| Formula | C11H10N2OS |
| 218.276 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Benzylthiouracil (BTU) is an antithyroid preparation. It is a thioamide, closely related to propylthiouracil.
Adverse effects
Benzylthiouracil has been associated with severe adverse effects, notably vasculitis and subsequent ANCA-positive glomerulonephritis, as well as isolated reports of lung damage.[1][2][3][4]
References
- ↑ Tieulie N, Huong DL, Andreu M et al. (2002). "[ANCA associated glomerulonephritis related to benzylthiouracil]". Rev Med Interne (in French) 23 (10): 853–6. doi:10.1016/S0248-8663(02)00694-X. PMID 12428489.
- ↑ Kaaroud H, Khiari K, Ben Moussa F, Barbouch S, Boussema E, Ben Maïz H (2002). "[Vasculitis with renal and pulmonary involvement in a patient receiving benzylthiouracil for Graves disease]". Rev Med Interne (in French) 23 (10): 857–61. doi:10.1016/S0248-8663(02)00704-X. PMID 12428490.
- ↑ Braham A, Houman MH, Rais L, Ben Gborbel I, Lamloum M, Miled M (2004). "[Benzylthiouracil induced ANCA-positive vasculitis]". Presse Médicale (in French) 33 (19 Pt 1): 1331–3. doi:10.1016/S0755-4982(04)98919-1. PMID 15615240.
- ↑ Thabet F, Sghiri R, Tabarki B, Ghedira I, Yacoub M, Essoussi AS (2006). "ANCA-associated diffuse alveolar hemorrhage due to benzylthiouracil". Eur J Pediatr 165 (7): 435–6. doi:10.1007/s00431-005-0053-4. PMID 16622664.
| ||||||||||||||||||||||||||||||||||||||||||||||